RNAC — Cartesian Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1453687 ·
Last close
$10.06
Market Cap
$304.37M
52W High
$11.00
52W Low
$5.77
ADV30
132,968
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -29,155,000 | 15,769,000 | 318,628,000 | 147,606,000 | 443,854,000 |
| Mar 2026 | 78,000 | — | -26,499,000 | -39,182,000 | 288,391,000 | 118,641,000 | 436,509,000 |
| Dec 2025 | 947,000 | — | -21,939,000 | -92,576,000 | 296,411,000 | 125,139,000 | 422,651,000 |
| Sep 2025 | 452,000 | — | -21,066,000 | -35,902,000 | 372,675,000 | 143,384,000 | 408,519,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-76,529,000
Investing CF
$-2,083,000
Financing CF
$65,925,000
CapEx
$-2,083,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.88
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-845,786,000
Inventory
—
Receivables
$196,000
ST Investments
—
EBIT TTM
$-52,883,000
Pretax Income TTM
$-161,084,000
Interest Exp TTM
$852,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,477,000
EBITDA
$-96,051,000
Free Cash Flow
$-47,480,376
Enterprise Value
$220,615,840
Total Cash
$147,606,000
Total Debt
$63,853,000
Shares Out
30,255,352
Trailing EPS
$-5.78
Book Value
$-4.17
ROE
—
ROA
-17.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,797,000 | -86,705,000 | -130,302,000 | 296,411,000 | 422,651,000 | — | -73,941,000 |
| Dec 2024 | 38,913,000 | -36,318,000 | -77,424,000 | 435,023,000 | 441,825,000 | — | -23,674,000 |
| Dec 2023 | 26,004,000 | -85,706,000 | -219,710,000 | 305,050,000 | 745,234,000 | — | -51,161,000 |
| Dec 2022 | 110,777,000 | 14,538,000 | 35,379,000 | 165,886,000 | 72,058,000 | — | -31,631,000 |
TTM Snapshot
Revenues TTM
$65,364,000
NetIncome TTM
$-22,301,000
OpCashFlow TTM
$0
Assets (Latest)
$435,023,000
Forward EPS
$-3.81
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $10.47 · call volume: 153 · put volume: 4
Expected Move to 2026-11-20:
±$6.05
(57.81%) —
implied range
$4.42 –
$16.52
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IFRX | InflaRx N.V. | $302.10M | $2.05 | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $310.75M | $0.29 | — |
| CYDY | CytoDyn Inc. | $297.23M | $0.22 | — |
| TTRX | Turn Therapeutics Inc. | $293.96M | $9.68 | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $293.71M | $0.17 | — |
News headlines (Yahoo Finance, 1h cache)
Cartesian Therapeutics Announces New Employment Inducement Grants
2026-08-07 11:00 · Yahoo
Cartesian Therapeutics Announces New Employment Inducement Grant
2026-06-12 20:05 · Yahoo
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
2026-06-09 11:00 · Yahoo
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
2026-05-26 11:00 · Yahoo
We're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate
2026-05-17 14:04 · Yahoo
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
2026-05-12 11:00 · Yahoo
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates
2026-04-30 12:30 · Yahoo
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-04-30 11:00 · Yahoo
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
2026-04-20 11:59 · Yahoo
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
2026-04-15 17:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.